Physical and Functional Coupling of CFTR and PDE3A by Penmatsa, Himabindu
University of Tennessee Health Science Center
UTHSC Digital Commons
Theses and Dissertations (ETD) College of Graduate Health Sciences
12-2009
Physical and Functional Coupling of CFTR and
PDE3A
Himabindu Penmatsa
University of Tennessee Health Science Center
Follow this and additional works at: https://dc.uthsc.edu/dissertations
Part of the Cells Commons
This Dissertation is brought to you for free and open access by the College of Graduate Health Sciences at UTHSC Digital Commons. It has been
accepted for inclusion in Theses and Dissertations (ETD) by an authorized administrator of UTHSC Digital Commons. For more information, please
contact jwelch30@uthsc.edu.
Recommended Citation
Penmatsa, Himabindu , "Physical and Functional Coupling of CFTR and PDE3A" (2009). Theses and Dissertations (ETD). Paper 204.
http://dx.doi.org/10.21007/etd.cghs.2009.0240.
Physical and Functional Coupling of CFTR and PDE3A
Document Type
Dissertation
Degree Name
Doctor of Philosophy (PhD)
Program
Biomedical Sciences
Track
Cell Biology and Biochemistry
Research Advisor
Anjaparavanda P. Naren, Ph.D.
Committee
Ioannis Dragatsis, Ph.D. Ivan C. Gerling, Ph.D. Donald B. Thomason, Ph.D. Xin Zhang, Ph.D.
DOI
10.21007/etd.cghs.2009.0240
This dissertation is available at UTHSC Digital Commons: https://dc.uthsc.edu/dissertations/204
 
 
 PHYSICAL AND FUNCTIONAL COUPLING OF CFTR AND PDE3A  
 
 
 
 
 
 
 
A Dissertation 
Presented for 
The Graduate Studies Council 
The University of Tennessee 
Health Science Center 
 
 
 
 
 
 
In Partial Fulfillment 
Of the Requirements for the Degree 
Doctor of Philosophy 
From The University of Tennessee 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
By 
Himabindu Penmatsa 
December 2009 
 
 
Copyright © 2009 by Himabindu Penmatsa 
All rights reserved
 ii 
DEDICATION 
 
 
This dissertation is dedicated to my parents, Rajeswari Penmatsa and 
Dattatreyavarma Penmatsa for being my strength, for their unconditional love, and 
constant support and to Dr. A. P. Naren for providing me this amazing opportunity. 
 
 iii 
ACKNOWLEDGEMENTS 
 
 
I am grateful to my mentor Dr. A. P. Naren for continued support and motivation 
all through my research training. His positive attitude towards research, knowledge and 
endurance has made my research journey very fruitful and enjoyable. I am also thankful 
to my former advisor Dr. G. N. Sastry for helping me realize my passion for research. 
 
I am thankful to my committee members Drs. Ioannis Dragatsis, Ivan Gerling, 
Donald Thomason, and Xin Zhang for their valuable suggestions and guidance.  
 
I would like to thank my lab members Li, Weiqiang, Sunitha, Aixia, and Veronica 
for technical assistance, help and support. 
 
I would like to thank Drs. Deborah Nelson and Guangping Zhang for technical 
assistance with single-channel recording experiments. I would like to thank Drs. Jeffrey 
Wine and Monal Sonecha for teaching me submucosal gland secretion assay. I would like 
to thank Drs. Suleiman Bahouth and Junming Yue for assistance with cloning. I thank 
Shirley Hancock, Patricia Page, and Larry Tague for assistance with dissertation 
preparation. 
 
I would like to thank and appreciate the grant support from American Heart 
Association and J. Paul Quigley award. 
 
I express my sincere gratitude to my mom and dad for their unconditional love 
and support and to my brother and sister-in-law for always being there in times of need. 
 
I truly appreciate the encouragement and immense moral support of my friends 
Sunitha, Deepthi, Vasanthi, Bharathi, and Surekha in times good and bad. 
 
 
 
 iv 
ABSTRACT 
 
 
Formation of multiple-protein macromolecular complexes at specialized 
subcellular microdomains increases the specificity and efficiency of signaling in cells. In 
this study, we demonstrated that phosphodiesterase type 3A (PDE3A) is physically and 
functionally coupled to cystic fibrosis transmembrane conductance regulator (CFTR). 
PDE3A inhibition increases cyclic adenosine 3′, 5′-monophosphate (cAMP) levels in a 
compartmentalized manner at the plasma membrane, which potentiates CFTR channel 
function and further clusters PDE3A and CFTR into microdomains. Actin skeleton 
disruption reduces PDE3A-CFTR interaction and segregates PDE3A from its interacting 
partners, thus compromising the integrity of the macromolecular complex. Consequently, 
PDE3A inhibition no longer activates CFTR channel function in a compartmentalized 
manner. Physiologically, formation of the CFTR-PDE3A-containing macromolecular 
complexes was investigated using pig trachea submucosal gland secretion model. PDE3A 
inhibition augments CFTR-dependent submucosal gland secretion and actin skeleton 
disruption decreases secretion. These findings are important in understanding the 
regulation of CFTR function by phosphodiesterases.
 v 
TABLE OF CONTENTS 
 
 
CHAPTER 1: INTRODUCTION.....................................................................................1 
 
Phosphodiesterases ........................................................................................................1 
Cyclic nucleotides and signaling .............................................................................1 
Cyclic nucleotide phosphodiesterases .....................................................................1 
Phosphodiesterase 3 ................................................................................................2 
Cystic Fibrosis Transmembrane Conductance Regulator..............................................2 
CFTR in fluid homeostasis and regulation ..............................................................2 
CFTR and mutations ................................................................................................2 
Actin cytoskeleton and CFTR...................................................................................5 
Protein-protein Interactions and cAMP Signaling.........................................................5 
CFTR protein-protein interactions ..........................................................................5 
PDE protein-protein interactions ............................................................................6 
CFTR and Tracheal Submucosal Gland Secretion ........................................................6 
Submucosal gland structure and function................................................................6 
Airway gland secretion in disease ...........................................................................9 
Hypothesis and Specific Aims .......................................................................................9 
 
CHAPTER 2: CLONING AND PURIFICATION OF PDE3A...................................11 
 
Materials and Methods.................................................................................................11 
Cloning of PDE3A into pcDNA3.1(-)-CFP and pcDNA3.1(-)-YFP vectors..........11 
Ligation independent cloning (LIC) of PDE3A into pTriEx-4 and pET-41  
vectors ....................................................................................................................11 
Generation of Flag and HA tagged PDE3A ..........................................................12 
Generation of HEK-293 and Calu-3 stable cell lines expressing Flag or HA 
tagged PDE3A .......................................................................................................13 
Purification of Flag, HA or HIS-S tagged PDE3A ................................................13 
Assay for enzymatic activity of purified full length PDE3A ..................................17 
Results..........................................................................................................................17 
 
CHAPTER 3: PDE3A AND CFTR: PHYSICAL AND FUNCTIONAL  
COUPLING VIA COMPARTMENTALIZED cAMP GENERATION ....................18 
 
Materials and Methods.................................................................................................18 
Reagents .................................................................................................................18 
Cell culture and transfections ................................................................................18 
Short circuit current (ISC) measurements...............................................................18 
Membrane preparation and immunoblotting.........................................................19 
Coimmunoprecipitation and immunoblotting ........................................................19 
Cross-linking the complex and immunoblotting ....................................................19 
Surface biotinylation and immunoblotting.............................................................20 
FRET microscopy and data analysis .....................................................................20 
 vi 
 vii 
Single particle tracking..........................................................................................21 
Submucosal gland secretion ..................................................................................22 
Surface labeling assay ...........................................................................................22 
Iodide efflux assay..................................................................................................22 
Immunofluorescence ..............................................................................................23 
AlphaScreen™ for PDE3A-CFTR interaction.......................................................23 
Cell-attached single-channel recording ................................................................24 
Statistical analyses.................................................................................................24 
Results..........................................................................................................................24 
PDE3A inhibition augments CFTR function by generation of  
compartmentalized cAMP ......................................................................................24 
PDE3A interacts with CFTR in a PKA-dependent manner ...................................31 
Cytoskeleton disruption reduces the physical and functional interaction  
between PDE3A and CFTR ...................................................................................46 
 
CHAPTER 4: DISCUSSION ..........................................................................................56 
 
Physical and Functional Coupling between CFTR and PDE3A..................................56 
Compartmentalized cAMP and PDE3A Signaling ......................................................56 
Physiological Relevance of CFTR-PDE3A-containing Macromolecular  
Complexes in Airway Gland Mucus Secretion............................................................57 
 
LIST OF REFERENCES................................................................................................59 
 
VITA..................................................................................................................................69 
 
LIST OF FIGURES 
 
 
Figure 1-1. Pictorial representation of PDE3A.................................................................3 
Figure 1-2. Pictorial representation of CFTR showing transmembrane domains, 
nucleotide binding (NBDs) domains, and regulatory (R) domain .................4 
Figure 1-3. CFTR macromolecular complex....................................................................7 
Figure 1-4. Submucosal gland structure ...........................................................................8 
Figure 2-1. Generation of PDE3A constructs with tags .................................................14 
Figure 2-2. Purification of full-length PDE3A ...............................................................15 
Figure 2-3. Purification of PDE3A-N-terminus .............................................................16 
Figure 3-1. CFTR dependent submucosal gland secretion increases with PDE3A  
 inhibition ......................................................................................................25 
Figure 3-2. Immunofluorescence and co-localization of PDE3A...................................27 
Figure 3-3. Ussing chamber data shows PDE3 inhibition augments CFTR function ....28 
Figure 3-4. Iodide efflux assay shows HEK-293-Flag-CFTR cells show increased  
 CFTR function with PDE3 inhibition ..........................................................29 
Figure 3-5. PDE3A is expressed in the membrane of HEK-293 and Calu-3 cells .........30 
Figure 3-6. Compartmentalized cAMP is generated with PDE3 inhibition ...................32 
Figure 3-7. PDE3 inhibition generates local cAMP whereas forskolin generates  
 global cAMP ................................................................................................33 
Figure 3-8. Schematic diagram for FRET ......................................................................34 
Figure 3-9. FRET reveals interaction between CFTR and PDE3A in live cells ............35 
Figure 3-10. CFP and YFP by themselves do not show FRET ........................................36 
Figure 3-11. Generation of HA and Flag tagged PDE3A and CFTR ...............................37 
Figure 3-12. Co-immunoprecipitation shows interaction between PDE3A and CFTR ...38 
Figure 3-13. Schematic diagram for alpha-screen assay ..................................................40 
Figure 3-14. Alpha-screen indicates direct interaction of purified CFTR and PDE3A....41 
Figure 3-15. Schematic diagram for surface labeling assay .............................................42 
Figure 3-16. Flag and HA tagged PDE3A are expressed on the plasma membrane ........43 
Figure 3-17. The majority of PDE3A is expressed on the membrane..............................44 
Figure 3-18. PKA phosphorylation does not alter surface expression of PDE3A............45 
Figure 3-19. Schematic diagram of single particle tracking assay ...................................47 
Figure 3-20. Single particle tracking of PDE3A with or without latrunculin B  
 shows different diffusion patterns................................................................48 
Figure 3-21. Latrunculin B decreases physical interaction between CFTR and  
 PDE3A .........................................................................................................49 
Figure 3-22. CFTR dependent tracheal submucosal gland secretion is not increased  
 with PDE3 inhibition when treated with latrunculin B................................51 
Figure 3-23. Surface expression of PDE3A is not altered in the presence of  
 latrunculin B.................................................................................................52 
Figure 3-24. Latrunculin treatment inhibits local increase of CFTR function by  
 PDE3 inhibition whereas global increase by forskolin is not altered ..........53 
Figure 3-25. Latrunculin B treatment alters open probablility of CFTR with PDE3  
 inhibition whereas forskolin response is unaltered ......................................54 
Figure 3-26. Model for PDE3A and CFTR coupling via compartmentalized cAMP ......55 
 viii 
LIST OF ABBREVIATIONS 
 
 
β2-AR  β2-adrenergic receptor 
 
µ  micro 
 
AC  adenylyl cyclase 
 
AKAP  A-kinase-anchoring protein 
 
AMP  adenosine monophosphate 
 
ANOVA  analysis of variance 
 
AR  adrenergic receptor 
 
ATP  adenosine triphosphate 
 
BIG  brefeldin-A inhibited guanine nucleotide exchange protein 
 
BSA  bovine serum albumin 
 
C  carboxyl end 
 
Ca2+  calcium 
 
CAL  CFTR associated ligand 
 
Calu-3  human, Caucasian, lung, adenocarcinoma 
 
CaM  calcium modulated protein 
 
cAMP  adenosine-3’, 5’-cyclicmonophosphate 
 
CAP70  cftr-associated protein-70kDa 
 
cDNA  complementary DNA 
 
CF  cystic fibrosis 
 
CFP  cyan fluorescent protein 
 
CFTR  cystic fibrosis transmembrane conductance regulator 
 
cGMP  guanosine-3’, 5’-cyclicmonophosphate 
 ix 
COPD  chronic obstructive pulmonary disease 
 
cpt.cAMP  8-(4-chlorophenylthio) adenosine-3’, 5’-cyclicmonophosphate 
 
D  diffusion coefficient 
 
DMEM-F12  Dulbecco’s modified eagle medium with nutrient mixture F-12 
 
DSP  dithiobis (succinimidyl) propionate 
 
DTT  dithiothreitol 
 
EDTA  ethylene diamine tetraacetic acid 
 
EM-CCD  electron multiplying charge coupled device 
 
EPAC  exchange protein directly activated by cAMP 
 
FRET  fluorescence resonance energy transfer 
 
G418  genetecin 
 
GPCR  G-protein coupled receptor 
 
GST  glutathione-S-transferase 
 
3H  tritium 
 
HA  hemagglutinin 
 
HBSS  Hank’s buffered salt solution 
 
HCl  hydrochloric acid  
 
HEK-293  human embryonic kidney-293 
 
Hepes  4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
 
HIS  histidine 
 
HRP  horse-radish peroxidase 
 
H2SO4  sulphuric acid 
 
IBMX  3-isobutyl-1-methylxanthine 
 
 x 
IgG  immunoglobulin G 
 
IκB  IkappaB protein 
 
Inh  inhibitor 
 
IP  immuno-precipitation 
 
IPTG  isopropyl-β-D-1 thiogalactopyranoside 
 
ISC  short-circuit current 
 
KCl  potassium chloride 
 
K2HPO4  dipotassium hydrogen phosphate 
 
KH2PO4  monopotassium hydrogen phosphate 
 
LIC  ligation independent cloning 
 
LPA2  lysophosphatidic acid receptor-2 
 
M  Molar 
 
mAb  monoclonal antibody 
 
mAKAP  muscle AKAP 
 
ME  mercaptoethanol 
 
MEM  minimal essential medium 
 
mg  milligram 
 
MgCl2  magnesium chloride 
 
min  minute 
 
ml  milliliter 
 
mm  millimeter 
 
mM  millimolar 
 
MRP4  multidrug resistance protein 4 
 
 xi 
MSD  mean squared displacement 
 
mV  millivolts 
 
N  amino terminal end 
 
Na+  sodium 
 
NaCl  sodium chloride 
 
NaHCO3  sodium bicarbonate 
 
NaI  sodium iodide 
 
NaNO3  sodium nitrate 
 
NBD  nucleotide binding domain 
 
N-FRETc  normalized corrected FRET 
 
ng  nanograms 
 
NHERF  Na+/H+ exchange regulatory factor 
 
nl  nanoliter 
 
nM  nanomolar 
 
P  probability 
 
PAGE  polyacrylamide gel electrophoresis 
 
PDE  phosphodiesterase 
 
PDZ  PSD95/DlgA/zo-1 
 
PKA  protein kinase A 
 
PMSF  phenyl methyl sulfonyl fluoride 
 
PSD95  post synaptic density protein 
 
PVDF  polyvinylidene difluoride 
 
RIPA  radioimmunoprecipitation 
 
 xii 
 xiii 
SD  standard deviation 
 
SDS  sodium dodecyl sulfate 
 
SEM  standard error of the mean 
 
SNAP-23  soluble NSF attachment protein of 23 kilodaltons 
 
SPT  single particle tracking 
 
TBS  Tris-base saline 
 
TMB  tetramethyl benzidine 
 
VIP  vasoactive intestinal peptide 
 
wt  wild-type 
 
YFP  yellow fluorescent protein 
 
ZO-1  zonula occludens-1 protein
CHAPTER 1: INTRODUCTION 
 
 
Phosphodiesterases 
 
 
Cyclic nucleotides and signaling 
 
Cyclic adenosine-3′,5′-monophosphate (cAMP) and cyclic guanosine-3′,5′-
monophosphate (cGMP) are important secondary messengers in the cells. Their levels 
have to be maintained precisely to regulate a variety of signaling cascades and cellular 
processes such as metabolism, cell proliferation and differentiation, secretion, vascular 
and airway smooth muscle relaxation and production of inflammatory mediators 
(Thompson et al., 2007; Zaccolo, 2006). cAMP effects are through activation of a limited 
number of effectors including cAMP-dependent protein kinase A (PKA), GTP-exchange 
protein EPACs (exchange proteins activated by cAMP) and via cAMP-gated ion channel 
(Halpin, 2008; Thompson et al., 2007). There is accumulating evidence for subcellular 
compartmentalization of cAMP, permitting control of cAMP-dependent signal 
transduction both spatially and temporally (Cooper, 2005; Halpin, 2008; Li et al., 2007). 
 
 
Cyclic nucleotide phosphodiesterases 
 
Cyclic nucleotide phosphodiesterases (PDEs) catalyze the hydrolysis of the 3′,5′-
phosphodiester bond of cyclic nucleotides and thus play pivotal roles in regulating 
intracellular concentrations and effects of secondary messengers cAMP and cGMP 
(Beavo, 1995; Degerman et al., 1997). PDEs have been reported to interact with 
regulatory proteins, scaffolding proteins and other signaling molecules to form 
macromolecular complexes which increase specificity and efficiency in cAMP signaling 
(Conti & Beavo, 2007). Eleven families of mammalian PDEs (PDE1-11) have been 
reported. Most of the families have more than one member. PDE3 family has two 
isoforms, PDE3A and PDE3B. PDE3s have distinctive characteristics which distinguish 
them from other PDEs, e.g., an insert of 44 amino acids in the catalytic domain and six 
hydrophobic putative transmembrane domains at the N-terminus. The structural 
organization of PDE3A and PDE3B protein is identical. However, the two isoforms 
exhibit tissue-specific expression and distinct cellular distributions (Conti & Beavo, 
2007; Degerman et al., 1997; Meacci et al., 1992). PDE3s have high affinities for both 
cAMP and cGMP (Km between 0.1-0.8µM) with Vmax for cAMP much higher than for 
cGMP (Beavo, 1995; Conti et al., 1995; Degerman et al., 1997; Manganiello et al., 1995). 
PDE3 is also called cGMP-inhibited PDE because of its inhibition by cGMP (Beavo, 
1995; Conti et al., 1995; Manganiello et al., 1995). PDE3A has been shown to be 
phosphorylated and activated by PKA, PKB and PKC in smooth muscle, oocytes and 
platelets respectively (Han et al., 2006; Hunter et al., 2009; Murthy et al., 2002).  
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Phosphodiesterase 3 
 
PDE3A is the major isoform expressed in the heart, lung, and platelets where it 
regulates physiological processes such as contraction of heart, relaxation of bronchial 
smooth muscle, and platelet aggregation (Shakur et al., 2001).  A pictorial representation 
of PDE3A protein structure is shown in Fig. 1-1. PDE3B is highly expressed in 
hepatocytes, adipocytes and beta cells and has been identified as a potential target for the 
treatment of obesity and diabetes (Thompson et al., 2007). Specific PDE3 inhibitors, 
presumably by inhibiting PDE3A, have been reported to enhance myocardial contractility 
and induce vascular and airway smooth muscle relaxation and have been used to treat 
heart failure and intermittent claudication (Halpin, 2008; Liu et al., 2001; Shin et al., 
2007). PDE inhibitors have also been shown to activate CFTR function in airway and 
colonic epithelial cells (Kelley et al., 1995; Liu et al., 2005).  
 
 
Cystic Fibrosis Transmembrane Conductance Regulator 
 
 
CFTR in fluid homeostasis and regulation 
 
CFTR is a cAMP-regulated chloride channel localized primarily at the apical 
surfaces of epithelial cells lining airway, gut, exocrine glands, etc., where it is responsible 
for transepithelial salt and water transport (Anderson et al., 1991; Bear et al., 1992; 
Riordan et al., 1989). CFTR function is also critical in maintaining fluid homeostasis, 
airway fluid clearance, and tracheal mucosal secretion in healthy and disease phenotypes 
(Riordan, 2008; Wine & Joo, 2004). CFTR is regulated by the activities of adenylyl 
cyclase (ACs) and PDEs through cAMP (Liu et al., 2005). A growing number of studies 
suggest that CFTR interacts directly or indirectly with other transporters, ion channels, 
scaffolding proteins, protein kinase, and cytoskeletal elements to form macromolecular 
complexes (Li et al., 2005; Li & Naren, 2005; Naren et al., 2003; Yoo et al., 2004). 
 
 
CFTR and mutations 
 
The CFTR gene encodes a 1480 amino acid chloride channel protein with twelve 
putative transmembrane domains (TMDs), two nucleotide binding domains (NBDs) and a 
regulatory (R) domain (Riordan, 2005). A pictorial representation of CFTR protein is 
shown in Fig. 1-2. Mutations in CFTR gene cause the expression of abnormal or non-
functional chloride channel in most cases thereby causing the disease cystic fibrosis (CF). 
Cystic fibrosis is a lethal autosomal recessive disorder usually associated with lung 
disease, pancreatic insufficiency, and elevated sweat chloride levels (Quinton, 1986; 
Rowntree & Harris, 2003). Although there are more than 1500 mutations described for 
the CFTR gene, mutations in CF patients can be divided into six classes (Amaral & 
Kunzelmann, 2007; Benharouga et al., 2001; Haardt et al., 1999; Rowntree & Harris, 
2003; Zielenski & Tsui, 1995; Zielenski, 2000). The class I mutations constitute  
 
 
 
 
Figure 1-1. Pictorial representation of PDE3A
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Figure 1-2. Pictorial representation of CFTR showing transmembrane domains, 
nucleotide binding (NBDs) domains, and regulatory (R) domain
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nonsense, splice and frame shift mutants that encode truncated forms of CFTR. The class 
II mutations are mostly processing mutants that get trapped in the endoplasmic reticulum 
(ER). The class III are regulation mutants and class IV are permeation mutants with 
partial loss of function. The class V mutations show reduced mRNA stability. The class 
VI mutations include C-terminal truncated CFTR which forms unstable mature protein 
with several fold faster degradation rate than WT-CFTR. 
 
 
Actin cytoskeleton and CFTR 
 
The role of actin filaments in regulating the function and organization of ion 
channels has been long established (Cantiello et al., 1991; Cantiello et al., 1993; 
Cantiello, 1996). Actin cytoskeleton disruption has been shown to affect both CFTR 
currents and the diffusion of the protein at the membrane (Cantiello, 2001; Ganeshan et 
al., 2007; Haggie et al., 2006). Actin depolymerizing reagent latrunculin B was shown to 
cause changes in CFTR dynamics (Haggie et al., 2006). Also, evidence for a direct 
interaction between purified CFTR and actin has been provided by reconstituting CFTR 
in lipid bilayer (Chasan et al., 2002). Given the evidence, it is logical to predict that actin 
cytoskeleton plays an important role in maintaining the integrity of CFTR protein-protein 
interactions as well. 
 
 
Protein-protein Interactions and Compartmentalized cAMP Signaling  
 
 
CFTR protein-protein interactions 
 
The physical and functional coupling of multiple proteins involved in a complex 
in compartmentalized domains is logical to achieve specific local signaling responses. 
The role of macromolecular complex formation in compartmentalized signaling has been 
elucidated for CFTR (Li & Naren, 2005; Li et al., 2007). The predominant adrenergic 
receptor isoform in the airway epithelia is β2-adrenergic receptor (Abraham et al., 2003). 
In airway epithelial cells, it has been shown that β2AR agonists activate CFTR function 
(Li & Naren, 2005). Also CFTR was shown to form macromolecular complexes with 
receptors and scaffolding proteins (LPA2, β2AR, NHERFs) to form a spatially, and 
temporally, regulated localized cAMP signaling complex (Li et al., 2005; Li et al., 2007; 
Naren et al., 2003). The role of PKA in regulating the function of CFTR in these 
signaling complexes has been proved as well (Naren et al., 2003). Earlier, syntaxin 1A 
and SNAP-23 were shown to bind CFTR and downregulate its activity (Naren et al., 
1997; Naren et al., 1998; Peters et al., 1999). Several PDZ proteins were shown to bind 
CFTR which include NHERF1, NHERF2, CAP70, CAL and IKEPP (Cheng et al., 2002; 
Hall et al., 1998; Short et al., 1998; Sun et al., 2000; Wang et al., 2000). Recently, it has 
been shown that CFTR couples to MRP4 via CAP70 scaffolding protein to form a 
temporally and spatially isolated microdomain for cAMP regulation of CFTR function 
(Li et al., 2007). Such protein-protein interactions have been shown to play key roles in 
pathophysiology as well. Altering CFTR function via its coupling to MRP4 or LPA2 has  
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been shown to inhibit secretory diarrhea in mice in vivo (Li et al., 2005; Li et al., 2007). 
A schematic of plausible CFTR macromolecular complex is shown in Fig. 1-3. 
 
 
PDE protein-protein interactions 
 
Phosphodiesterases such as PDE1, PDE3, PDE4, PDE6, PDE7 & PDE8 have 
been shown to form higher order complexes and to be involved in protein-protein 
interactions that regulate their function (Conti & Beavo, 2007). Interactions like CaM 
with PDE1 and Xap2 with PDE4A5 are a few examples to implicate the importance of 
protein-protein interactions in regulation of PDE activity (Bolger et al., 2003; Florio et 
al., 1996). Shank 2 has been shown to interact with PDE4D and bring it physically close 
to CFTR (Lee et al., 2007). PDEs have also been shown to interact with scaffolding 
proteins like AKAPs bringing protein kinases into the macromolecular complex (Dodge-
Kafka et al., 2006). For example, mAKAP and AKAP 450 have been shown to bind 
PDE4D3 and form a complex, which can be tightly regulated by PKA in micro-domains 
(Dodge et al., 2001; Tasken et al., 2001). PKA in this complex has been shown to 
increase protein-protein interactions of PDE in the complex, and alter cAMP levels 
locally by activating PDE. PDE4 has also been shown to interact with arrestin and this 
interaction has been suggested to play an important role in receptor signaling (Perry et al., 
2002). PDE3 interaction with 14-3-3 and PDE 8 interaction with IκB are examples of 
other PDE protein-protein interactions (Onuma et al., 2002; Wu & Wang, 2004). The 
importance of these macromolecular complexes at a physiological level has been shown 
in PDE4D null mice, in which, the dysfunction of the complex has been implicated to 
play a role in progression of cardiac failure and arrhythmias seen under stress in these 
mice (Lehnart et al., 2005). The existence of PDEs as dimers or oligomers in the cell has 
also been reported for several isoforms (Conti & Beavo, 2007). There is a speculation 
that loss of oligomerization leads to loss of catalytic activity, also, a change in affinity of 
catalytic domain to certain inhibitors has been observed (Conti & Beavo, 2007; Richter & 
Conti, 2004).  
 
 
CFTR and Tracheal Submucosal Gland Secretion  
 
 
Submucosal gland structure and function 
 
Submucosal glands in the trachea secrete several substances including mucins, 
anti-microbial substances and fluid which primarily form the mucus as a protective line 
of defense. These glands contain ducts and secretory tubules (Meyrick et al., 1969). The 
secretory tubules contain serosal and mucosal cells. A pictorial representation of 
submucosal gland structure is shown in Fig. 1-4. Mucous cells secrete mucins and serous 
cells secrete fluid and anti-microbial substances thereby providing a medium of 
protection (Basbaum et al., 1990; Meyrick & Reid, 1970). CFTR protein expression is 
found predominantly in the serosal cells of the submucosal glands and also in the apical 
plasma membrane of ciliated cells (Engelhardt et al., 1992; Jacquot et al., 1993). CFTR is 
 
 
 
 
Figure 1-3. CFTR macromolecular complex. Modified from source: Naren, A.P., Cobb, 
B., Li, C., Roy, K., Nelson, D., Heda, G.D., Liao, J., Kirk, K.L., Sorscher, E.J., Hanrahan, 
J. & Clancy, J.P. (2003). A macromolecular complex of beta 2 adrenergic receptor, 
CFTR, and ezrin/radixin/moesin-binding phosphoprotein 50 is regulated by PKA. Proc 
Natl Acad Sci U S A. 100, 342-346. Copyright © (2003) National Academy of Sciences, 
U. S. A. 
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Figure 1-4. Submucosal gland structure. Modified from source: Ballard, S.T. & 
Spadafora, D. (2007). Fluid secretion by submucosal glands of the tracheobronchial 
airways. Respir Physiol Neurobiol. 159, 271-277. Copyright © (2007) Elsevier.
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believed to play pivotal role in fluid secretion and transport by actively transporting 
chloride leading to sodium transport and thus driving osmotic water transport (Matthay et 
al., 2002; Matthay et al., 2005). The early evidence for defect in chloride transport in 
cystic fibrosis came from studies done in sweat ducts of CF patients (Quinton, 1983). 
Several studies later confirmed that chloride, bicarbonate and liquid transport by 
submucosal glands were important for lung function and the dysfunction of this transport 
causes CF lung pathophysiology (Inglis et al., 1998; Trout et al., 1998). Submucosal 
gland secretion in pig has been reported to be at least in part CFTR-dependent and this 
dependence has also been reported in human and mouse tracheal submucosal gland 
secretion (Choi et al., 2007; Ianowski et al., 2008). CF submucosal glands showed no 
response to VIP and forskolin when compared to healthy non-CF submucosal glands 
implicating an important role of CFTR in tracheal submucosal gland secretion (Wine & 
Joo, 2004). Also, early studies suggested that CF submucosal glands secrete thick and 
viscous mucus which obstruct the glands and impair mucociliary clearance thereby 
promoting bacterial infections (Ballard & Spadafora, 2007; Zuelzer & Newton, 1949). 
More recent studies using fluorescence recovery after photobleaching (FRAP) showed 
that the CF gland secretion was more viscous and abnormal (Salinas et al., 2005). 
 
 
Airway gland secretion in disease 
 
Diseases like chronic obstructive pulmonary disease (COPD), asthma and cystic 
fibrosis involve mucus hypersecretion, enlargement of submucosal glands, mucus plugs 
leading to obstruction, and tracheobronchial submucosal gland hypertrophy (Barnes, 
1996; Fahy et al., 1992; Finkbeiner, 1999; Samet & Cheng, 1994). Although the 
characteristics of mucus plugs differ in asthma and COPD, they are inherent features of 
both these diseases (Dunnill et al., 1969; Rogers, 2003). Obstruction of airway with thick 
mucus and impaired mucus clearance is a major problem in airway diseases like asthma 
(Rogers, 2004). Owing to the central role of CFTR in serosal fluid secretion and overall 
fluid transport in healthy lung phenotype, it becomes mandatory to restore CFTR 
function in disease phenotype. Methods or substances that increase CFTR function may 
substantially help in restoring at least part of lung function by correcting fluid secretion 
and transport. 
 
 
Hypothesis and Specific Aims 
 
The unifying hypotheses of my study is that phosphodiesterase 3A (PDE3A) 
exists as a higher order complex, its interaction with cystic fibrosis transmembrane 
conductance regulator (CFTR; a PKA activated chloride channel) is regulated by cAMP, 
and that inhibition of PDE3A augments CFTR function.  
 
The three specific aims of my study were to answer the questions:  
 
• Does PDE3A inhibition increase CFTR function, can PDE3A and CFTR interact, 
and does PKA regulate the interaction at the plasma membrane?  
 9 
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• Can cAMP dynamics be monitored at the plasma membrane, and does PDE3A 
inhibition increase cAMP at the plasma membrane?  
• Can we disrupt PDE3A-CFTR interaction, and does this alter CFTR function? 
CHAPTER 2: CLONING AND PURIFICATION OF PDE3A 
 
 
Materials and Methods 
 
 
Cloning of PDE3A into pcDNA3.1(-)-CFP and pcDNA3.1(-)-YFP vectors 
 
A human full length PDE3A cDNA clone was obtained from Open Biosystems 
(Huntsville, AL) in pCR4-TOPO vector. PDE3A was PCR amplified using Xho I and 
KpnI forward and reverse primers. The primers used are: 
 
PDE3A-XhoI-Forward: 
AGTCCTCGAGATGGCAGTGCCCGGCGACGCTGCACGA 
PDE3A-KpnI-Reverse: 
ATGCGGTACCTCACTGGTCTGGCTTTTGGGTTGGTAT 
 
The amplified PCR product was cleaned using the Qiagen kit and eluted in 20 µL 
DNA grade water. The PCR cleaned sample was run on a 1% agarose gel. The product 
was gene cleaned using Qiagen’s (Valencia, CA) QIAEX II kit. The cleaned product was 
ligated into pcDNA3.1 (-)-CFP and pcDNA3.1 (-)-YFP which had been restriction 
digested with XhoI and KpnI using Takara (Madison, WI) DNA ligation kit ver. 1, and 
the ligated product was transformed into DH5α cells. Six clones were picked for culture 
overnight; minipreps were done using Qiagen miniprep kit and the DNA was sent for 
sequencing to Molecular Resource Center (MRC, UTHSC). The sequence was confirmed 
to be pcDNA3.1 (-)-CFP-PDE3A and pcDNA3.1 (-)-YFP-PDE3A. 
 
 
Ligation-independent cloning (LIC) of PDE3A into pTriEx-4 and pET-41 vectors 
 
Human full length PDE3A and regulatory (R), catalytic, N-terminal and C-
terminal domains were PCR-amplified. The PCR products were cleaned using Qiagen 
PCR purification kit and eluted in 20 µL DNA grade water. The PCR-cleaned DNA was 
further used for ligation independent cloning (LIC) using Ek/LIC cloning kit from 
Novagen (EMD, Gibbstown, NJ). Primers used for LIC cloning were: 
 
PDE3A-full-length-LIC Forward: 
GACGACGACAAGATGGCAGTGCCCGGCGACGCTGCACGA 
PDE3A-full-length-LIC Reverse: 
GAGGAGAAGCCCGGTTCACTGGTCTGGCTTTTGGGTTGGTAT  
PDE3A (N-tail) 1-61 amino acid 
Forward: PDE3A-full-length-LIC Forward 
Reverse: GAGGAGAAGCCCGGTCTAAAGTTTCCGAGAGCTCCGGAGCGGCTG 
PDE3A (R-domain) 255-750 amino acid 
Forward: GACGACGACAAGATGGTGGAACAAATCTTGCCGCAGTCCGCG 
Reverse: GAGGAGAAGCCCGGTCTAAGGAATATCCCTATATCCAATCTCCAA 
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PDE3A (Catalytic domain) 751-1035 amino acid 
Forward: GACGACGACAAGATGTATCATAACAGAATCCATGCCACTGAT 
Reverse: GAGGAGAAGCCCGGTCTAATCTCCTGACTCATCGCTGTCTTCCAC 
PDE3A (C-tail) 1036-1141 amino acid 
Forward: GACGACGACAAGATGACTGATGACCCAGAAGAAGAGGAGGAA 
Reverse: PDE3A-full-length-LIC Reverse  
 
14.6 µL of PCR-purified DNA was taken into a clean centrifuge tube and 2 µL 
each of 10X T4 DNA polymerase buffer and 25 mM deoxy-adenosine triphosphate 
(dATP) were added. 1 µL of 100 mM dithiothreitol (DTT) and 0.4 µL of T4 DNA 
polymerase were added to make a 20 µL total volume reaction mix. The reaction was 
started by adding the enzyme and stirring gently and incubated at 22°C for 30 min. The 
reaction was then stopped by inactivating the enzyme with 75°C incubation for 20 min. 
This T4 DNA polymerase-treated insert can be annealed into any Ek/LIC vectors. 
pTriEx-4 and pET-41 vectors were used to ligate this insert. For the ligation reaction, 1 
µL Ek/LIC vector pTriEx-4 or pET-41 and 2 µL of T4 DNA polymerase-treated insert 
were used and incubated at 22°C for 5 min. Then, 1 µL of 25 mM EDTA was added for 5 
min at 22°C. The ligated product was transformed into Novablue cells. Three clones were 
picked for each vector, plasmid DNA was isolated and sent for sequencing. The 
sequences were confirmed to be PDE3A. pTriEx-4 has a HIS-S tag whereas pET41 has a 
GST-HIS-S tag, and thus pTriEx-4-PDE3A with HIS-S tag and pET41-PDE3A with 
GST-HIS-S tags were generated. pTriEx-4 was chosen for eukaryotic expression and 
pET-41 for bacterial protein purification. 
 
 
Generation of Flag and HA tagged PDE3A 
 
To generate full length PDE3A with Flag or HA tag on the putative first outer 
loop, PDE3A was sub-cloned into pcDNA3 using XhoI and KpnI restriction enzymes. 
After generating pcDNA3-PDE3A construct, site-directed mutagenesis was used to insert 
a Flag or HA tag between amino acid position 104 and 105. Quickchange site-directed 
mutagenesis kit (Stratagene, La Jolla, CA) was used and mutagenic primers were 
designed based on the kit guidelines. The primers (forward and reverse for Flag or HA 
insertion) were as follows: 
 
PDE3A-104-Flag-Forward 
GAGGAGGAAGCAGCCGACTATAAAGACGACGACGACAAACCGGGAGCAGA
AGGG 
PDE3A-104-Flag-Reverse 
CCCTTCTGCTCCCGGTTTGTCGTCGTCGTCTTTATAGTCGGCTGCTTCCTCCTC 
PDE3A-104-HA-Forward 
GAGGAGGAAGCAGCCTATCCATATGACGTCCCAGACTATGCCCCGGGAGCAG
AAGGG 
PDE3A-104-HA-Reverse 
CCCTTCTGCTCCCGGGGCATAGTCTGGGACGTCATATGGATAGGCTGCTTCCT
CCTC 
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For the mutant strand synthesis reaction, 30 ng of template DNA and 125 ng each 
of forward and reverse primers were used in a 50 µL reaction for PCR. The amplified 
PCR product was treated with DpnI and transformed into XL-gold ultracompetent cells. 
Six clones were cultured, plasmid DNA isolated, and sent for sequencing. The sequences 
confirmed the presence of a Flag or HA tag at amino acid position 104 in full length 
PDE3A. A schematic for generation of PDE3A constructs is shown in Fig. 2-1. 
 
 
Generation of HEK-293 and Calu-3 stable cell lines expressing Flag- or HA-tagged 
PDE3A 
 
HEK-293 or Calu-3 cells were transfected with pcDNA3-Flag-PDE3A or 
pcDNA3-HA-PDE3A and selected with G418 (0.4 mg/ml) to generate stable cell lines 
expressing Flag or HA tagged PDE3A. HEK-293 or Calu-3 cells were plated on 60 mm 
dishes at a density of approximately 106 cells per dish. The next day, cells at about 80% 
confluence were transfected with pcDNA3-Flag-PDE3A or pcDNA3-HA-PDE3A or 
control using Lipofectamine 2000 (Invitrogen, Carlsbad, CA). About 5 µl of 
Lipofectamine was used for 2 µg of DNA. After 48 h, selection was started by replacing 
the media with media containing 0.4 mg/ml G418. Media was replaced everyday with 
G418 media for 2-3 weeks till colonies of stable cells survived and all other cells died. 
These colonies were picked by trypsinization and maintained in G418 media. 
 
 
Purification of Flag-, HA-, or HIS-S-tagged PDE3A 
 
HEK-293 cells were plated on 10 cm dishes, transfected with pcDNA3-Flag-
PDE3A, pcDNA3-HA-PDE3A or pTriEx-4-PDE3A (full length or domain specific 
constructs) and grown for 48 h. The cells were then washed with PBS twice and lysed 
with PBS containing 0.2% Triton-X-100 and protease inhibitor cocktail (aprotinin, 
leupeptin, pepstatin and phenylmethylsulphonyl fluoride (PMSF)). The cell lysate was 
mixed on a shaker for 10 min at 4°C and centrifuged for 10 min at 13,000 rpm. The 
supernatant containing total protein was immunoprecipitated using α-Flag, α-HA beads 
or S-protein agarose beads overnight. The beads with bound protein were washed and the 
protein was eluted with 100 mM glycine (pH 2.2) and quickly neutralized with 150 mM 
tris (pH 8.8). The eluted protein was subjected to SDS-PAGE on 4-15% gel (Bio-Rad, 
Hercules, CA) and transferred to PVDF membrane and either visualized with Gel Code 
Blue or immunoblotted with α-Flag-HRP, α-HA-HRP or α-S-HRP antibody. A 
coomassie gel with purified PDE3A is shown in Fig. 2-2. 
 
To test if we could purify large amount of fusion protein, recombinant GST-His-
S-PDE3A-N-terminal protein was induced in E.coli using IPTG (0.2 mM). The fusion 
protein was purified using affinity chromatography (glutathione beads). The GST-fusion 
protein was eluted using 10 mM glutathione in TBS (pH 7.4) and was further purified 
using size exclusion chromatography. A chromatogram and coomassie gel for PDE3A-N-
terminus is shown in Fig. 2-3. 
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Figure 2-1. Generation of PDE3A constructs with tags
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Figure 2-2. Purification of full-length PDE3A
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Figure 2-3. Purification of PDE3A-N-terminus 
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Assay for enzymatic activity of purified full length PDE3A 
 
We used a radioactive 3H-cAMP phosphodiesterase assay for measuring PDE3A 
enzymatic activity (Thompson et al., 1979). In the first step, PDE converts the radioactive 
cAMP into AMP. In the second step, nucleosidase from snake venom further converts 
AMP to adenosine. Ion exchange chromatography (AG® 1-X 8 resin; Bio-Rad, Hercules, 
CA) was used to separate cAMP and AMP from adenosine. Radioactive adenosine was 
measured in a scintillation counter. 
 
 
Results 
 
In this part of the study, we demonstrated the cloning and purification of PDE3A 
with various tags. The fluorescent CFP and YFP tags are critical to study protein-protein 
interactions in live cells using imaging techniques like FRET. Flag, HA, GST, HIS and S 
tags are crucial for biochemical studies like co-immunoprecipitation and protein 
purification. Generation of pcDNA3-PDE3A with various epitope tags was important for 
making stable cell lines. Stable cell lines expressing significant amount of PDE3A is the 
first and most essential requirement to carry out any biochemical studies. This is 
mandatory not only to purify significant amounts of protein but also to identify 
interacting partners. HEK-293 cells were chosen due to the ease of transfection, their 
human origin and response to various agonists. Also, we have HEK-293 cells stably 
expressing CFTR, which are known to respond to adenosine and β-adrenergic receptor 
agonists. We also found endogenous expression of PDE3A in HEK-293 cells by 
immunoblotting. This made the cell line more appealing and useful for our studies on 
PDE3A-CFTR interaction. Calu-3 (lung serosal epithelial cell line) on the other hand 
endogenously expresses both CFTR and PDE3A and also forms transepithelial membrane 
resistant monolayers when grown on transwell supports and thus is an ideal choice for 
our CFTR functional studies. Thus, we made stables of Flag-PDE3A and HA-PDE3A in 
both HEK-293 and Calu-3 cell lines. We purified full length PDE3A (~ 130 kDa band) 
from both the cell lines. To verify that the full-length protein was indeed PDE3A, we sent 
the purified protein out for mass spectrometry and the results identified the protein as 
PDE3A. Further, we purified recombinant GST-HIS-S-PDE3A domains (N-terminal, C-
terminal, regulatory and catalytic) from E.coli. To confirm that the purified full-length 
PDE3A was functional, we used radioactive cAMP phosphodiesterase assay and found 
the protein had enzymatic activity when present on beads but loses activity soon after 
elution. We also confirmed that the insertion of Flag or HA tag on the first outer loop of 
PDE3A does not effect the activity of the protein. 
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CHAPTER 3: PDE3A AND CFTR; PHYSICAL AND FUNCTIONAL COUPLING 
VIA COMPARTMENTALIZED cAMP GENERATION 
 
 
Materials and Methods 
 
 
Reagents 
 
Trequinsin, cilostazol and rolipram were purchased from Biomol (Plymouth 
Meeting, PA). Forskolin was obtained from Tocris (Ellisville, MO). Isoproterenol was 
purchased from Calbiochem (EMD, Gibbstown, NJ). DSP was obtained from Pierce 
(Thermo Fisher, Rockford, IL). Adenosine, IBMX, cpt-cAMP, latrunculin B, carbachol, 
and indomethacin were purchased from Sigma-Aldrich (St. Louis, MO). 
 
 
Cell culture and transfections 
 
HEK293 cells were cultured in DMEM-F12 media containing 10% serum and 1% 
penicillin/streptomycin and maintained in a 5% CO2 incubator at 37oC. Calu-3 cell line 
was purchased from ATCC (Manassas, VA) and cultured in MEM media containing 15% 
serum, 1% penicillin/streptomycin, 1 mM sodium pyruvate and 1X non-essential amino 
acids. Lipofectamine 2000 was used to express plasmids containing CFTR or PDE3A in 
both HEK293 and Calu-3 cell lines according to the manufacturer’s instructions. Stable 
cell lines were generated by selection using 0.4 mg/ml G418 (geneticin). 
 
 
Short circuit current (ISC) measurements 
 
Polarized lung serosal cells (Calu-3) monolayers were grown on Costar Transwell 
permeable supports (filter area 0.33cm2) until the monolayer reached a resistance of 
~1500 ohms and the transwell was mounted in an Ussing chamber. Short circuit currents 
were measured as described previously (Li et al., 2005). Epithelia were bathed in 
Ringer’s solution (mM) (Basolateral: 140 NaCl, 5 KCl, 0.36 K2HPO4, 0.44 KH2PO4, 1.3 
CaCl2, 0.5 MgCl2, 4.2 NaHCO3, 10 HEPES, 10 glucose, pH 7.2, [Cl-] = 149), and low Cl- 
Ringer’s solution (mM) (Apical: 133.3 Na-gluconate, 5 K-gluconate, 2.5 NaCl, 0.36 
K2HPO4, 0.44 KH2PO4, 5.7 CaCl2, 0.5 MgCl2, 4.2 NaHCO3, 10 HEPES, 10 mannitol, pH 
7.2, [Cl-] = 14.8) at 37°C, and saturated with 95% O2 and 5% CO2. The monolayers were 
bathed in a low chloride Ringer’s solution on the apical side and normal Ringer’s solution 
on the basolateral side. A 2 mV pulse was applied every 1 min throughout the experiment 
to check for the integrity of the epithelia. PDE3-specific inhibitor cilostazol (10-100 µM) 
was added to apical and basolateral sides. Forskolin (20 µM) was added to both sides for 
maximal response. CFTRinh-172 (20 µM) was added to the apical side. For ISC 
measurements with actin cytoskeleton disruption of the cells, latrunculin B (1 µM) was 
added to both apical and basolateral sides after pre-treating the cells with latrunculin B (1 
µM) for 30 min. 
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Membrane preparation and immunoblotting 
 
For detecting PDE3A expression and localization in cells using Western blotting, 
crude membrane and cytosolic fractions were isolated. In order to prepare crude 
membrane and cytosol, HEK-293 parental cells, Calu-3 cells or Calu-3 cells transfected 
with HA-PDE3A were grown on 10 cm dishes. The dishes were washed with PBS and 
scraped in PBS and the cells pelleted at 600 g for 5 min at 4°C. The pellet was then 
resuspended by incubation with hypotonic lysis buffer (10 mM HEPES, 1 mM EDTA, 
protease inhibitor cocktail, pH 7.2) for 10 min before lysis by 10 strokes in Dounce 
homogenizer, followed by 15 strokes in the presence of equal volume of sucrose buffer 
(500 mM sucrose, 1 mM EDTA, 10 mM HEPES, pH 7.2). The lysate was spun at 6000 g 
for 20 min at 4°C to obtain post-mitochondrial supernatant. Crude membrane was 
collected by centrifuging the supernatant at 100,000 g for 45 min at 4°C. The pellet was 
resuspended in isotonic buffer (250 mM sucrose, 1 mM EDTA, 10 mM HEPES, pH 7.2) 
to collect crude membrane and supernatant was used for cytosolic fraction. The protein 
was mixed with Laemmli sample buffer (5x; containing 2.5% β-mercaptoethanol), 
denatured, subjected to SDS-PAGE on 4-15% gel and transferred to PVDF membrane. 
PDE3A mAb from Novus Biologicals (Littleton, CO) was used for immunoblotting. 
 
 
Coimmunoprecipitation and immunoblotting 
 
Cells transfected with Flag-CFTR and HA-PDE3A or only HA-PDE3A were 
lysed using lysis buffer (1x PBS, containing 0.2% Triton-X-100 and protease inhibitors 
phenylmethylsulfonyl fluoride 1 mM, pepstatin-A 1 µg/ml, leupeptin 1 µg/ml, aprotinin 1 
µg/ml). The lysate was centrifuged at 16,000 g for 10 min at 4 ºC and the clear 
supernatant was subjected to immunoprecipitation using α-Flag beads (Sigma-Aldrich, 
St.Louis, MO). The immunoprecipitated beads were washed three times with lysis buffer 
and the protein was eluted from the beads using Laemmli sample buffer (5x; containing 
2.5% β-mercaptoethanol). The eluates were denatured and subjected to SDS-PAGE on 4-
15% gel. The protein was transferred to PVDF membrane. PDE3A mAb from Novus 
Biologicals (Littleton, CO) was used for immunoblotting. 
 
 
Cross-linking the complex and immunoblotting 
 
Thiol-cleavable, amine-reactive, homobifunctional cross-linker dithiobis 
succinimidyl propionate (DSP, 1 mM) was used to cross-link protein complex in HEK-
293 cells grown on 10 cm dishes expressing both Flag-CFTR and HA-PDE3A. HEK-293 
cells expressing only Flag-CFTR were used as control. The cells were pre-treated with 1 
µM latrunculin B for 30 min at 37°C and then cross-linked with 1 mM DSP for 5 min at 
37°C. The reaction was quenched by lysing the cells with ice-cold RIPA buffer (140 mM 
NaCl, 1% Nonidet P40, 0.5% Na-deoxycholate, 0.1% Na-dodecyl sulphate and 50 mM 
Tris-HCl, pH 8.0) containing protease inhibitor cocktail. The supernatant was spun at 
20,000 rpm for 10 min. After taking 100 µL of total protein for input, the rest of the 
protein was immunoprecipitated by adding α-HA beads overnight. The beads were 
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washed twice with RIPA buffer and the cross-linked complex was eluted with 100 mM 
glycine (pH 2.2) and quickly neutralized with 150 mM Tris (pH 8.8). For cleaving the 
disulphide bond of DSP and separating the proteins, 2.5% β-mercaptoethanol was added 
to the sample Laemmli buffer. The eluted proteins were mixed with Laemmli sample 
buffer (5x; containing 2.5% β-mercaptoethanol), denatured, subjected to SDS-PAGE, 
transferred to PVDF membrane and immunoblotted using α-M3A7-CFTR antibody from 
Millipore (Billerica, MA). 
 
 
Surface biotinylation and immunoblotting 
 
Cells expressing HA-PDE3A were surface biotinylated with EZ-Link Sulfo-NHS-
LC-Biotin from Pierce (Rockford, IL) for 1 h at 4°C, lysed, and immunoprecipitated 
using α-HA agarose beads (Sigma-Aldrich, St.Louis, MO). The biotinylated purified HA-
PDE3A was pulled down using streptavidin beads (Pierce, Rockford, IL) for 1 h at room 
temperature. The beads were spun down to collect unbound fraction, and the beads 
contained the bound fraction. The samples were mixed with Laemmli sample buffer (5x; 
containing 2.5% β-mercaptoethanol), denatured, subjected to SDS-PAGE on 4-15% gel, 
transferred to PVDF membrane and immunoblotted with α-PDE3A mAb from Novus 
Biologicals (Littleton, CO). 
 
 
FRET microscopy and data analysis 
 
For ratiometric FRET, HEK 293 cells expressing CFP-EPAC-YFP were grown on 
glass-bottom dishes (MatTek, Ashland, MA), washed twice with Hank’s balanced salt 
solution (HBSS) and mounted on an inverted Olympus wide-field microscope (IX51, U-
Plan Fluorite 60x 1.25 NA oil-immersion objective) for FRET imaging. The stage was 
maintained at 37°C constantly and the cells were maintained in the dark in HBSS. After 
establishing the baseline, PDE inhibitors were added as indicated. Ratiometric FRET 
imaging was performed as described previously (Li et al., 2007). Time-lapse images were 
obtained with 1x1 binning, 100-300 ms exposure time and 1 min intervals. Images were 
acquired using an EM CCD camera (Hamamatsu) mounted on an Olympus IX51. The 
light source used was 300W xenon lamp with a neutral density filter. A JP4 CFP/YFP 
filter set was used for image capture (Chroma, Brattleboro, VT) which includes a 430/25 
nm excitation filter, a double dichroic beam splitter and two emission filters (470/30 nm 
for CFP and 535/30 nm for FRET emission) alternated by filter-change controller 
Lambda 10-3 (Sutter instruments, Novato, CA). Slidebook 4.2 software was used for data 
analysis. Following background subtraction, multiple regions of interest (10-20) were 
selected (3-5 cells) for data analysis using ratio module. The emission ratio (CFP/FRET) 
was obtained from CFP and FRET emission of background subtracted cells.  
 
For direct sensitized emission FRET, HEK 293 cells were transiently transfected 
with pCDNA3-CFP-PDE3A or pCDNA3-YFP-CFTR or both using Lipofectamine 2000. 
Single transfected cells were used to acquire CFP or YFP only images for bleed through 
calculations. Double transfectants were used for data collection using CFP/YFP filter 
 20 
sets. The cells were split at low density at 20-40% confluence into a cover slip bottom 
dish (MatTek; Ashland, MA), washed twice with warm HBSS and 2 ml of HBSS was 
added. Cells were imaged in a dark room at 37°C. After acquiring images without PKA 
agonists as 0 time point images, PKA activating cocktail (Forskolin 10 µM, IBMX 100 
µM, cpt-cAMP 200 µM) was added and images were acquired at 2, 4, 6, 8 and 10 min 
intervals. Corrected FRET was calculated on a pixel-by-pixel basis for the entire image 
by using equation: FRETc = FRET - (0.5 × CFP) - (0.06 × YFP), where FRET, CFP, and 
YFP correspond to background-subtracted images of cells co-expressing CFP-PDE3A 
and YFP-CFTR acquired through the FRET, CFP, and YFP channels, respectively 
(Galperin & Sorkin, 2003). The factors 0.5 and 0.06 are the fractions of bleed-through of 
CFP and YFP fluorescence, respectively, through the FRET filter channel. The corrected 
FRET (FRETc) was normalized with donor CFP intensity (FRETc/CFP), yielding the 
normalized corrected FRET (N-FRETc), and the intensity of N-FRETc images was 
presented in monochrome mode, stretched between the low and high renormalization 
values, according to a intensity to color mapped lookup table with black indicating low 
values and white indicating high values. All calculations were performed using the 
Channel Math and FRET modules of the SlideBook 4.2 software (Intelligent Imaging 
Innovations; Denver, CO).  
 
 
Single particle tracking 
 
Calu-3 cells stably expressing HA-PDE3A were grown on 35 mm glass bottom 
dishes (MatTek, Ashland, MA). Cells were washed twice with phosphate buffered saline 
containing 6 mM glucose and 1 mM sodium pyruvate (PBS/Glu/NaPyr) and blocked with 
PBS/Glu/NaPyr containing 4% bovine serum albumin (BSA) for 10 min. Cells were then  
incubated with biotin α-HA antibody (1 µg/ml, Sigma-Aldrich, St. Louis, MO) for 15 
min, washed five times, followed a second incubation with streptavidin-conjugated Qdot-
655 (0.1 nM, Invitrogen, Carlsbad, CA) for 2 min, washed 8 times, and immediately 
mounted on an Olympus inverted microscope (IX51), and the images were captured with 
Hamamatsu EM-CCD camera at 1-3 frames per second (fps) for 1-3 min with 50 ms 
exposure time, 100x oil-immersion objective (NA 1.40), xenon (300W lamp) light 
source, and SlideBook 4.2 software. Qdot 655-A BrightLine® high brightness and 
contrast single band filter set (Semrock, Rochester, NY) was used for collecting data. 
Single particle tracking was done using particle tracking module of SlideBook 4.2 
software, which generates trajectories and also calculates MSD. Diffusion coefficient (D) 
was calculated by linear squares fitting using points 1-5 on the MSD curve. 5-10 cells 
were used for plotting histograms of diffusion coefficient. To monitor changes in 
diffusion with cytoskeletal disruption, cells were pre-treated with latrunculin B (1 µM, 30 
min) and latrunculin B was also added to the buffer during the course of the experiment. 
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Submucosal gland secretion 
 
Submucosal gland secretion was monitored and analyzed as described by Wine’s 
laboratory (Joo et al., 2001). Freshly collected pig trachea was placed in cold Krebs-
Ringer bicarbonate buffer (120 mM NaCl, 25 mM NaHCO3, 3.3 mM KH2PO4, 0.8 mM 
K2HPO4, 1.2 mM MgCl2, 1.2 mM CaCl2, 10 mM D-glucose and 1 µM indomethacin). 
The submucosal layer was carefully dissected from the cartilage and a 1 cm piece was 
mounted in a chamber mucosal side up. The mucosal side was wiped and quickly air-
dried with 95% O2 and 5% CO2 gas. A thin layer of water-saturated mineral oil was 
applied to the mucosal side. The tissue was constantly maintained at 37°C and gassed 
with 95% O2 and 5% CO2 after mounting. To establish a baseline, Krebs-Ringer 
bicarbonate buffer was added to the serosal side. PDE3 inhibitor cilostazol, CFTR 
inhibitor 172 and latrunculin B (10 µM) were added to the serosal side after monitoring 
basal secretion. Carbachol was added at the end of the experiment to check for the 
viability of submucosal glands. Images were collected at 1 min time intervals with a 
digital camera (Motic Images 2.0 ML software, National Optical, San Antonio, TX) 
attached to a stereoscopic microscope (National Optical, San Antonio, TX) and analyzed 
using ImageJ software (NIH, Bethesda, MD). A 1 mm x 1 mm grid was placed on the 
tissue in the last image for area measurements. Volume was calculated from area using 
the formula v = Πr3 and rate was calculated as slope of volume vs. time plot by fitting at 
least four points using linear regression. 
 
 
Surface labeling assay 
 
Cells expressing Flag or HA-PDE3A grown on 35 mm dishes were fixed with 
3.7% formaldehyde for 10 min, blocked with 1% BSA for 30 min, and treated with α-
Flag or HA-HRP (0.2 µg/ml) for 90 min. HRP substrate 1-step Ultra TMB (Pierce, 
Rockford, IL) was added to the dishes for about 10-20 min, and the reaction was stopped 
by adding equal amount of 2 M H2SO4 and the absorbance was read at 450 nm. To detect 
any altered surface expression with PKA phosphorylation, cells were pre-treated with 
forskolin (20 µM) for 10 min, fixed, surface labeled and then assayed. To detect the 
effects of latrunculin B on PDE3A surface expression levels, Calu-3 cells expressing HA-
PDE3A were pre-treated with latrunculin B (1 µM) for 30 min and then proceeded for 
surface labeling as described above. 
 
 
Iodide efflux assay 
  
CFTR mediated halide efflux was measured using iodide efflux assay. HEK-293 
cells expressing wild type CFTR were grown on 60 mm dishes, and iodide efflux was 
assayed as described. Briefly, cells were loaded for 60 min at room temperature with 
loading buffer (136 mM NaI, 137 mM NaCl, 4.5 mM KH2PO4, 1 mM CaCl2, 1 mM 
MgCl2, 10 mM glucose, 5 mM HEPES, pH 7.2). Extracellular NaI was washed away 
thoroughly (5 times) with efflux buffer (136 mM NaNO3 replacing 136 mM NaI in the 
loading buffer) and cells were equilibrated for 1 min in a final 1 ml aliquot. The first four 
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aliquots were used to establish a stable base line in efflux buffer alone. Agonist (1 µM 
adenosine with or without 100 µM cilostazol or 5 µM isoproterenol with or without 20 
µM trequinsin) was added to the efflux buffer and samples were collected every 1 min for 
6 min in the continued presence of agonists (i.e., the efflux buffer used for subsequent 
replacements also contained agonists at the same concentration). The iodide 
concentration of each aliquot was determined using an iodide-sensitive electrode 
(Thermo Scientific, Waltham, MA) and converted to iodide content (nanomoles/min). 
HEK 293 parental cells in the presence of agonist forskolin were used as a negative 
control.  
 
 
Immunofluorescence 
 
Calu-3 cells on glass-bottom dishes were directly used after fixing with 3.7% 
formaldehyde or paraffin embedded pig trachea was processed for immunostaining. 
Paraffin embedded pig trachea was sectioned. The slides with sections were treated with 
protease to retrieve the antigen. The cells on dishes and antigen retrieved sections were 
blocked with PBS with 4% BSA and 0.2% Triton-X-100, inside a humidifying chamber 
for 2 h. The slides or dishes were treated with rabbit polyclonal α-PDE3A from Santa 
Cruz Biotechnology (Santa Cruz, CA) at 1:50 dilution overnight. Normal rabbit IgG was 
used for negative control. The slides were treated for 1 h with secondary antibody α-
rabbit AlexaFluor 488 (Molecular probes, Invitrogen, Eugene, OR) at 1:500 dilution and 
1:1000 dilution of propidium iodide. Images were taken on a Carl-Zeiss (Thornwood, 
NY) confocal microscope. For co-localization experiments, rabbit polyclonal α-PDE3A 
and mouse monoclonal α-CFTR primary antibodies were used and AlexaFuor 488 and 
568 secondary antibodies were used. Normal rabbit and mouse IgG were used for 
negative control. Calu-3 cells were fixed for 30 min at -20°C using acetone-methanol and 
further fixed with 3.7% formaldehyde.  
 
 
AlphaScreenTM for PDE3A-CFTR interaction 
 
We used AlphaScreen™ (Amplified Luminescent Proximity Homogeneous 
Assay) to study CFTR-PDE3A interaction. Purified full-length Flag tagged CFTR and 
biotinylated HA-PDE3A were used and 2103 EnVision multilabel plate reader was used 
to measure the fluorescence between acceptor and donor beads. AlphaScreen™ FLAG™ 
(M2) detection kit was used to detect the interaction between purified full-length biotin-
(HA)-PDE3A and Flag-(M2)-wt-CFTR. In brief, starting from 100 nM final 
concentration, biotin-(HA)-PDE3A was serially diluted (in 1/2 log dilution series) in 
assay buffer [1x PBS, 0.1% BSA, 0.05% Tween 20 (v/v), pH 7.2] containing Flag-wt-
CFTR (100 nM final concentration). The resulting solutions were incubated at room 
temperature for 30 min. Each sample solution (15 µl) was transferred to a white opaque 
384-well microplate (OptiPlateTM-384, PerkinElmer, MA) in triplicates and into which 
anti-FLAG (M2) acceptor beads (5 µl, 20 µg/ml final concentration) were added and 
incubated for 30 min at room temperature. Streptavidin donor beads (5 µL, 20 µg/ml final 
concentration) were then added and incubated for 2 h at room temperature. The plate was 
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read on an EnVisionTM 2103 Multilabel Reader (PerkinElmer, MA) or FLUOstar-
Omega plate reader with AlphaScreen™ capability (BMG labtech, Durham, NC). 
 
 
Cell-attached single-channel recording 
 
Single-channel recordings were obtained from Calu-3 cells as described 
previously (Li et al., 2007). The pipette solution contained either forskolin or cilostazol 
(10-20 µM) to activate CFTR channels. Both bath and pipette solution contained (in mM) 
140 N-methyl-D-glucamine, 140 HCl, 2 CaCl2, 2 MgCl2, 10 HEPES, pH 7.4. Single 
channel currents were recorded at a test potential of +80 mV (reference to the cell 
interior) delivered from the recording electrode, and were filtered at 100 Hz and sampled 
at 2 kHz.  
 
 
Statistical analyses 
 
Statistical analyses were done using Student’s t-test (2-tailed) or ANOVA (single-
factor), and p < 0.01 or p < 0.05 was considered significant. All the results are 
represented as mean + SEM with n being the number of experiments. 
 
 
Results 
 
 
PDE3A inhibition augments CFTR function by generation of compartmentalized cAMP  
 
Submucosal glands secretion plays important roles in maintaining airway and 
lung health. It is usually stimulated by agonists that elevate cAMP or Ca2+ level and has 
been reported to be at least in part CFTR-dependent (Choi et al., 2007; Ianowski et al., 
2008). To explore the physiological relevance of functional coupling between CFTR and 
PDE3A, we used pig tracheal submucosal gland secretion model. Pig is considered a 
closer model to human cystic fibrosis (CF), and a CF pig model is available for studying 
CFTR function (Rogers et al., 2008). After established basal secretion, a specific PDE3 
inhibitor, cilostazol (100 µM), was added to the serosal side to inhibit PDE3A. Cilostazol 
has been approved for treatment of intermittent claudication since 1999 in the USA and 
for treatment of peripheral artery occlusive disease (PADO) in Japan since 1988 
(Thompson et al., 2007). As shown in Fig. 3-1, upon PDE3A inhibition, we observed a 3-
fold increase in mean mucosal secretion rate (from 0.5 nl/min/gland basal secretion rate 
to 1.5 nl/min/gland). This increased secretion was inhibited by treatment of the trachea 
with a specific CFTR channel inhibitor, CFTRinh-172 (50 µM), suggesting that the 
increased secretion is CFTR-dependent. Carbachol, an agonist which stimulate the glands 
secretion by elevating Ca2+ level, was added at the end of the experiments to check for 
the viability of submucosal glands (Fig. 3-1). 
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Figure 3-1. CFTR dependent submucosal gland secretion increases with PDE3A 
inhibition 
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The expression and localization of PDE3A in pig trachea was studied by 
immunohistochemical analysis using a PDE3A-specific antibody and α-rabbit AlexaFluor 
488 as the secondary antibody.  We also investigated the localization of PDE3A in Calu-
3 cells, a widely used model for submucosal gland serous cells (Ianowski et al., 2008). 
Non-immune rabbit IgG was used as a negative control in these studies. As can be seen in 
Fig. 3-2, PDE3A is primarily localized at the plasma membrane of epithelial cells of pig 
trachea and at the plasma membrane of Calu-3 cells. It is to be noted that CFTR is also 
expressed at the plasma membrane of Calu-3 cells (Li et al., 2004; Li et al., 2005; Naren 
et al., 2003). We also used immunofluorescence to detect co-localization between 
PDE3A and CFTR endogenously. Calu-3 cells showed co-localization of PDE3A and 
CFTR (Fig. 3-2). 
 
To investigate if the functional coupling of PDE3A and CFTR can be observed in 
live cells, we used two CFTR Cl- channel function assays. The first one was to measure 
CFTR-dependent short circuit current (ISC) in polarized Calu-3 cells mounted in an 
Ussing chamber (Li et al., 2007). Consistent with the observation of Drumm’s group 
(Kelley et al., 1995), PDE3A inhibition increased CFTR Cl- channel function. In the 
presence of PDE3 inhibitors trequinsin (1-20 µM) or cilostazol (10-100 µM), we 
observed a dose-dependent increase in CFTR-mediated currents which was inhibited by 
CFTRinh-172 (20 µM) (Fig. 3-3). Forskolin (20 µM), a adenylyl cyclase stimulator 
which elicits a global increase of cAMP and maximally stimulates CFTR function (Li et 
al., 2005; Li et al., 2007), was used as positive control for these studies. It is to be noted 
that inhibition of PDE3A induced smaller magnitude of ISC response compared to that 
stimulated by forskolin (20 µM). In the case of using cilostazol, the ISC could be further 
increased to a maximal level by using forskolin (20 µM) suggesting that inhibition of 
PDE3A generates localized cAMP rather than global cAMP.  
 
The second CFTR functional assay we used was to measure the iodide efflux 
from HEK293 cells overexpressing Flag-wt-CFTR.  Adenosine or isoproterenol were 
used to activate CFTR channel function in these studies and HEK293 parental cells 
stimulated by forskolin were used as negative control.  As can be seen in Fig. 3-4, 
inhibition of PDE3A increased CFTR-mediated iodide efflux. In the presence of 
cilostazol (100 µM), the iodide efflux increased > 50% when a low dose of adenosine (1 
µM) was used. Similarly, by using trequinsin (20 µM), the iodide efflux increased > 50% 
when a low dose of isoproterenol (5 µM) was used. Adenosine is a cAMP-elevating 
ligand which has been reported to stimulate CFTR channel function in a 
compartmentalized manner at the apical cell membranes when being used at low (< 20 
µM) concentrations (Huang et al., 2001; Li et al., 2007). Isoproterenol is a β adrenergic 
receptor (β-AR) agonist which acts via activation of β-AR and AC to induce cAMP. 
 
The expression and localization of PDE3A in HEK293 cells and Calu-3 cells was 
studied by Western blotting. Calu-3 cells transfected with HA-PDE3A were used as 
positive control (Fig. 3-5). The results show that PDE3A is expressed in the membrane of 
these cells. 
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Figure 3-2. Immunofluorescence and co-localization of PDE3A 
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Figure 3-3. Ussing chamber data shows PDE3 inhibition augments CFTR function  
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Figure 3-4. Iodide efflux assay shows HEK-293-Flag-CFTR cells show increased CFTR 
function with PDE3 inhibition 
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Figure 3-5. PDE3A is expressed in the membrane of HEK-293 and Calu-3 cells 
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To further characterize the localization of cAMP upon PDE3A inhibition and to 
investigate the possible mechanism through which CFTR functionally couples to PDE3A, 
a FRET-based cAMP sensor, CFP-EPAC-YFP, was transfected into HEK293 cells and 
then subjected to ratiometric fluorescence resonance energy transfer (FRET) 
measurements. This highly sensitive, unimolecular fluorescent cAMP indicator allows to 
monitor cAMP dynamics in intact cells with very high temporal and spatial resolution (Li 
et al., 2007; Ponsioen et al., 2004). As can be seen from Fig. 3-6, upon PDE3A inhibition 
by using cilostazol, cAMP levels (represented by CFP/FRET emission ratio) increased in 
a dose-dependent manner. More importantly, the increase of cAMP levels occurs mainly 
at the edge area of the cells, suggesting a highly compartmentalized cAMP accumulation 
at the plasma membrane. Interestingly, addition of a PDE4 inhibitor, rolipram (10µM), 
induced a global increase in cAMP levels (indicated by the uniform increase of the 
emission ratio in the entire cytoplasm) which is similar to the effect seen with forskolin 
stimulation (20µM; Fig. 3-7). It seems reasonable to propose that in these cells PDE3A is 
probably involved in compartmentalized cAMP signaling whereas PDE4 regulates global 
cAMP levels. Taken together, our data showed that PDE3A is functionally coupled to 
CFTR. Inhibition of PDE3A augments CFTR function by generation of highly 
compartmentalized cAMP. 
 
 
PDE3A interacts with CFTR in a PKA-dependent manner 
 
Given the evidence of functional coupling, we continued to investigate whether a 
physical coupling between PDE3A and CFTR existed. Towards this, we co-transfected 
HEK293 cells with CFP-PDE3A and YFP-CFTR and measured the direct sensitized 
emission FRET in live cells. A schematic diagram of FRET assay is shown in Fig. 3-8. 
As shown in Fig. 3-9, the two proteins interacted at the plasma membrane as indicated by  
the FRET signals. More importantly, this interaction increased by almost 70% 
(normalized FRET) upon treatment with a PKA-activating cocktail (forskolin 10 µM, 
IBMX 100 µM, and cpt-cAMP 200 µM), suggesting that the interaction between CFTR 
and PDE3A is PKA-dependent. Phosphorylation increases the binding between PDE3A 
and CFTR. To confirm that CFP and YFP do not show FRET by themselves, we 
transfected cells with CFP and YFP only and observed that there was no significant 
FRET between the fluorophores (Fig. 3-10). 
 
Coimmunoprecipitation and immunoblotting were also used to detect the 
interaction between PDE3A and CFTR. HEK293 cells were co-transfected with HA-
PDE3A and Flag-CFTR, immunoprecipitated using α-Flag beads and immunoblotted for 
PDE3A. Cells transfected with HA-PDE3A were used as negative control. For all the 
protein interaction studies, we generated PDE3A constructs with either Flag or HA tag on 
the first outer loop at position 104 and CFTR with Flag tag at position 901 on the fourth 
outer loop (Fig. 3-11). As shown in Fig. 3-12, HA-PDE3A can be coimmunoprecipited 
with Flag-CFTR, suggesting interaction exists between these two proteins which 
corroborate the FRET data. 
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Figure 3-6. Compartmentalized cAMP is generated with PDE3 inhibition 
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Figure 3-7. PDE3 inhibition generates local cAMP whereas forskolin generates global 
cAMP 
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Figure 3-8. Schematic diagram for FRET
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Figure 3-9. FRET reveals interaction between CFTR and PDE3A in live cells
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Figure 3-10. CFP and YFP by themselves do not show FRET
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Figure 3-11. Generation of HA and Flag tagged PDE3A and CFTR
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Figure 3-12. Co-immunoprecipitation shows interaction between PDE3A and CFTR 
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To investigate if the interaction between PDE3A and CFTR is direct, we purified 
full-length Flag-CFTR and full-length biotinylated HA-PDE3A. Amplified luminescent  
proximity homogeneous assay (AlphaScreenTM) FLAG (M2) detection kit was used to 
study the interaction between these two purified proteins. A schematic diagram for 
alphascreen assay is shown in Fig. 3-13. The AlphaScreenTM assay is a highly sensitive 
method which can be used to detect direct interactions between interacting partners at 
femtomolar concentrations (Ullman et al., 1996). For these studies, we kept Flag-CFTR 
concentration constant (100 nM final concentration) and used increasing concentrations 
of biotinylated HA-PDE3A (10 pM to 100 nM). As can be seen from Fig. 3-14, HA-
PDE3A interacts directly with Flag-CFTR at nanomolar concentrations and in a dose-
dependent manner.  
 
To test whether the increased interaction between PDE3A and CFTR by PKA 
phosphorylation is due to the altered surface expression levels of PDE3A, we used 
surface labeling assay to study the expression of Flag- or HA-PDE3A at the plasma 
membrane of Calu-3 cells. A schematic diagram for surface labeling assay is shown in 
Fig. 3-15. Calu-3 cells endogenously expressing PDE3A were used as control. The 
formaldehyde-fixed cells were labeled with α-Flag-HRP or α-HA-HRP and incubated 
with HRP substrate 1-step Ultra TMB. The reaction was stopped by addition of 2 M  
H2SO4 and absorbance was read at 450 nm. As shown in Fig. 3-16, Flag- or HA-PDE3A 
is expressed at the plasma membrane of Calu-3 cells and the tags are indeed on the outer 
loop of the protein.  
 
To further verify the surface expression of PDE3A, we surface labeled HEK293 
cells expressing HA-PDE3A with a cell-impermeable biotinylating reagent Sulfo-NHS-
LC-biotin at 4°C, lysed the cells and immunoprecipitated using α-HA agarose beads. The 
purified biotinylated HA-PDE3A was pulled down using streptavidin beads and the 
bound and unbound fractions were immunoblotted for PDE3A. HEK293 parental cells 
were used as negative control. We found that more than 90% of PDE3A is present at the 
plasma membrane of transfected HEK293 cells (Fig. 3-17). Next, we investigated the 
effects of PKA-phosphorylation on the surface expression levels of Flag-PDE3A. Calu-3 
cells transfected with Flag-PDE3A were pre-treated with PKA activating agonist 
(forskolin, 20 µM) and then subjected to surface labeling as described above. The results 
showed that PKA-phosphorylation does not increase PDE3A surface expression levels as 
indicated by the unchanged absorbance between forskolin pre-treated cells and untreated 
cells (Fig. 3-18). 
 
Based on these results, we proposed that, PDE3A and CFTR are in close 
proximity to each other at the plasma membrane of epithelial cells (e.g., Calu-3 cells). 
Inhibition of PDE3A generates highly compartmentalized cAMP, which further clusters 
PDE3A and CFTR into microdomains and augments CFTR channel function in a 
compartmentalized manner.  
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Figure 3-13. Schematic diagram for alphascreen assay 
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Figure 3-14. AlphaScreen™ indicates direct interaction of purified CFTR and PDE3A 
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Figure 3-15. Schematic diagram for surface labeling assay 
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Figure 3-16. Flag and HA tagged PDE3A are expressed on the plasma membrane
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Figure 3-17. The majority of PDE3A is expressed on the membrane
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Figure 3-18. PKA phosphorylation does not alter surface expression of PDE3A 
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Cytoskeleton disruption reduces the physical and functional interaction between PDE3A 
and CFTR  
 
All of the described data suggested the physical and functional coupling between 
PDE3A and CFTR. The next question we asked was: can we dissociate the clusters of 
PDE3A and CFTR at the plasma membrane and would this dissociation alter specifically 
PDE3A-dependent CFTR Cl- channel function? Actin cytoskeleton has been shown to be 
important for maintaining CFTR in highly restricted domains on the plasma membrane 
(Jin et al., 2007). Actin filament organization has also been shown to play functional role 
in the activation and regulation of CFTR Cl- channel function (Cantiello, 1996; Chasan et 
al., 2002; Ganeshan et al., 2007).  Therefore, we continued to investigate the effects of 
cytoskeleton disruption on the physical and functional coupling between PDE3A and 
CFTR to see if cytoskeleton plays an important role in the physical and functional 
integrity of macromolecular complexes. Latrunculin B, a specific actin-disrupting reagent 
which causes actin filament depolymerization, was used for these purposes. 
 
We first investigated the effects of actin cytoskeleton disruption on HA-PDE3A 
dynamics in live Calu-3 cells by using single particle tracking (SPT) method. A 
schematic diagram of single particle tracking assay is shown in Fig. 3-19. SPT is a 
powerful method to study the dynamics of individual proteins in the plasma membrane of 
live cells (Chen et al., 2006). HA-PDE3A (HA tag on the first outer loop at position 104) 
was labeled with biotin α-HA antibody and then conjugated to streptavidin-conjugated 
Qdot-655 for monitoring lateral mobility on the plasma membrane. The mean diffusion 
coefficient of PDE3A (0.0025 µm2/s) we observed in this study is similar to that reported 
for CFTR (Bates et al., 2006; Jin et al., 2007), indicating the confined diffusion of 
PDE3A. As shown in Fig. 3-20, when the cells were treated with latrunculin B (1 µM), a 
significant increase in the mean squared displacement (MSD) and diffusion coefficient of 
PDE3A was observed (mean diffusion coefficient: 0.0117 µm2/s; a 4.7-fold increase 
compared to the untreated cells). It is reasonable to propose that actin cytoskeleton 
disruption compromised the integrity of multiprotein complex and caused PDE3A to 
move freely, thus uncoupling PDE3A from the CFTR-containing complex. 
 
To further investigate if the physical interaction between PDE3A and CFTR was 
reduced with cytoskeleton disruption, we co-transfected HEK293 cells with Flag-CFTR 
and HA-PDE3A and cross-linked these two proteins in live cells using 
dithiobissuccinimidyl propionate (DSP; 1 mM) with or without latrunculin B treatment. 
The cells were then lysed in RIPA buffer (containing 1 M urea) to disrupt all interactions 
except antigen-antibody interaction and the proteins were co-immunoprecipitated using 
α-HA beads and immunoblotted for CFTR. HEK 293 cells expressing only Flag-CFTR 
were used as negative control. DSP is a thiol-cleavable, amine-reactive homobifunctional 
cross-linker which has been used to cross-link proteins of interest in live cells (Li et al., 
2004). The result showed that latrunculin B treatment led to a significant decrease in 
PDE3A-CFTR interaction (Fig. 3-21). 
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Figure 3-19. Schematic diagram of single particle tracking assay
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Figure 3-20. Single particle tracking of PDE3A with or without latrunculin B shows 
different diffusion patterns 
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Figure 3-21. Latrunculin B decreases physical interaction between CFTR and PDE3A 
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We also tested the effects of actin disruption on functional coupling between 
PDE3A and CFTR. To test our hypothesis in a physiologically relevant system, we used 
latrunculin B in pig trachea submucosal gland secretion studies. As can be seen in  
Fig. 3-22, when treated with latrunculin B, a significant decrease (> 90%) in cilostazol-
activated and CFTR-dependent mean mucosal secretion was observed. The data are 
consistent with the findings from the ISC studies. We observed that latrunculin B itself 
can cause a small decrease of mean mucosal secretion rate.  We ruled out the possibility 
of altered surface expression of PDE3A on latrunculin B treatment by using surface 
labeling assay which showed that the surface expression level of PDE3A is not 
significantly changed (Fig. 3-23).  
 
CFTR-dependent short-circuit currents were measured in polarized Calu-3 cells 
mounted in an Ussing chamber. As shown in Fig. 3-24, ISC measurements in cells treated 
with latrunculin B showed that the potentiating effects of PDE3A inhibition (cilostazol: 
10-100 µM) on CFTR-dependent currents decreased by almost 65-80% compared to the 
cells without latrunculin B treatment.  However, it is to be noted that the maximally-
stimulated ISC by forskolin (by increasing global cAMP) remained unaffected by 
latrunculin B treatment (Fig. 3-24).  
 
Cell-attached single-channel recording in Calu-3 cells strongly supported our 
hypothesis and shed more mechanistic insights into the physical and functional coupling 
between PDE3A and CFTR and its actin cytoskeleton dependence. Cilostazol or forskolin 
was applied in the pipette to active CFTR channel function. As shown in Fig. 3-25, there 
was no significant change in single channel conductance for cells activated by either 
cilostazol or forskolin with or without latrunculin B treatment.  CFTR channel open 
probability was significantly decreased in cilostazol activated currents when treated with 
latrunculin B. However, forskolin activated currents were not altered with latrunculin B 
treatment.  
 
These data clearly indicated that PDE3A inhibition activated CFTR channel 
function in a compartmentalized manner and the coupling between these two proteins 
was actin cytoskeleton dependent. Cumulatively, our findings provided clear evidence 
that, 1) PDE3A was physically, and functionally, coupled to CFTR at the plasma 
membrane through compartmentalized cAMP; 2) inhibition of PDE3A generated high 
levels of compartmentalized cAMP which further clustered the two proteins into 
microdomains and potentiated CFTR Cl- channel function; 3) cytoskeleton disruption 
decreased CFTR-PDE3A interaction, probably by scattering CFTR and PDE3A away 
from each other and compromising the integrity of the macromolecular signaling 
complexes, leading to the loss of compartmentalized cAMP signaling. Consequently, 
inhibition of PDE3A no longer potentiated CFTR Cl- channel function in 
compartmentalized fashion. A model for CFTR and PDE3A coupling via 
compartmentalized cAMP generation is shown in Fig. 3-26. 
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Figure 3-22. CFTR dependent tracheal submucosal gland secretion is not increased with 
PDE3 inhibition when treated with latrunculin B
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Figure 3-23. Surface expression of PDE3A is not altered in the presence of latrunculin B 
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Figure 3-24. Latrunculin treatment inhibits local increase of CFTR function by PDE3 
inhibition whereas global increase by forskolin is not altered
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Figure 3-25. Latrunculin B treatment alters open probablility of CFTR with PDE3 
inhibition whereas forskolin response is unaltered 
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Figure 3-26. Model for PDE3A and CFTR coupling via compartmentalized cAMP
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CHAPTER 4: DISCUSSION 
 
 
 It is now well accepted that the formation of multiple-protein macromolecular 
complexes at specialized subcellular microdomains increases the specificity and 
efficiency of signaling in cells (Li & Naren, 2005; Li et al., 2007).  The main goal of this 
study was to investigate the physical and functional coupling between CFTR Cl- channel 
and PDE3A and its physiological relevance in airway gland mucus secretion.  
 
 
Physical and Functional Coupling between CFTR and PDE3A 
 
In this study, we found that PDE3A is expressed at the plasma membrane of 
epithelial cells of pig trachea, Calu-3 cells, and HEK293 cells. These data are supported 
by results from immunohistochemical analysis, Western blotting and cell surface labeling 
studies. We demonstrated that CFTR directly interacts with PDE3A in a PKA-dependent 
manner by using FRET, cross-linking, co-immunoprecipitation and AlphaScreenTM 
assay. We also observed the functional coupling between PDE3A and CFTR Cl- channel 
function. Inhibition of PDE3A augmented CFTR Cl- channel function as seen in ISC and 
iodide efflux measurements. Studies on cAMP localization and dynamics by using a 
FRET-based cAMP sensor, CFP-EPAC-YFP, showed that, upon PDE3A inhibition, 
cAMP was generated in highly compartmentalized fashion at the plasma membrane. All 
these data indicated that CFTR and PDE3A form macromolecular complexes at the 
plasma membrane through compartmentalized cAMP. This hypothesis was further 
supported by the facts that actin cytoskeleton disruption decreased CFTR-PDE3A 
interaction, probably by scattering CFTR and PDE3A away from each other and 
compromising the integrity of the macromolecular complexes. Consequently, inhibition 
of PDE3A no longer activated CFTR Cl- channel function in compartmentalized fashion 
as evidenced by cell-attached single-channel recording studies, ISC measurements and pig 
tracheal submucosal gland secretion studies in the presence of latrunculin B, an actin 
skeleton disrupting reagent. Based on these results, we propose a model to depict the 
mechanism through which the physical and functional coupling between PDE3A and 
CFTR Cl- channel occurs.   
 
 
Compartmentalized cAMP and PDE3A Signaling 
 
One of the key features of cAMP/PKA signal transduction system has been 
suggested to be the compartmentalization of its signaling enzymes and effectors that 
generates localized cAMP and activates PKA at distinct subcellular locations (Zaccolo, 
2006). PDEs have been shown to play vital roles in such compartmentalized signaling 
processes. The emerging idea is that it is the compartmentalization of individual PDEs, 
rather than total expression level, which is of vital importance in modulating localized 
intracellular cAMP levels (Zaccolo, 2006).  Kinase-anchoring proteins (AKAPs) have 
been reported to play key roles in the assembly and organization of such 
compartmentalized cAMP/PKA signaling. AKAPs anchor PKA and PDEs to specific 
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intracellular locations in close vicinity to specific modulators and targets to achieve 
signaling specificity and efficiency (Langeberg & Scott, 2005; McConnachie et al., 
2006). Tasken et al. reported that PDE4D3 and PKA form a signaling complex in the 
centrosomal area which is coordinated by the centrosomal AKAP450 and regulates 
accurate spatiotemporal cAMP signals (Tasken et al., 2001). Lee et al. demonstrated that 
a PDZ-containing protein, Shank2, competes with NHERF1 for binding to CFTR. 
Shank2 associates with PDE4D and tethers it to CFTR complex and thus attenuates 
cAMP/PKA signals (Lee et al., 2007).  Pozuelo et al. reported that PDE3A binds directly 
to 14-3-3 proteins in a phosphorylation-dependent manner and PDE3A also binds to 
plectin, a cytoskeletal linker protein (Pozuelo Rubio et al., 2005). More recently, 
Puxeddu et al. demonstrated that PDE3A interacts with brefeldin A-inhibited guanine 
nucleotide-exchange proteins (BIG1 and BIG2) in HeLa cell cytosol via 
compartmentalized cAMP signaling with spatial and temporal specificity (Puxeddu et al., 
2009).  
 
In this study, we report a previously unknown physical and functional coupling 
between CFTR and PDE3A and propose that they form a signaling macromolecular 
complex at the plasma membrane. Other signaling components such as specific G 
protein-coupled receptors (GPCRs), G proteins (Gs), AC, PKA and anchoring proteins 
(AKAPs) may also be present in the proposed macromolecular complexes which 
synergistically regulate compartmentalized cAMP signaling and specificity of CFTR 
activation.  
 
 
Physiological Relevance of CFTR-PDE3A-containing Macromolecular Complexes in 
Airway Gland Mucus Secretion    
 
Regulation of CFTR channel function via its interaction with PDE3A is of 
physiological and pathophysiological importance owing to: 1) CFTR is the primary 
cAMP-activated Cl- channel on the apical membrane of airway epithelia, thus playing 
critical roles in controlling the electrolyte/fluid balance and mucociliary clearance 
process (Pilewski & Frizzell, 1999), 2) phosphodiesterase inhibition remains a viable area 
of therapy for the treatment of airway diseases such as asthma and COPD (Fan Chung, 
2006). Submucosal gland secretion has been reported to play important roles in 
maintaining airway and lung health and CFTR has been shown to play important roles in 
such process. This idea is supported by the observations that CF glands have altered 
response to secretagogues compared with normal glands (Ianowski et al., 2008) and by 
the fact that in CF patients the airway host defenses system are compromised, leading to 
chronic secondary bacterial infections and inflammation in the lung and respiratory 
failure (Pilewski & Frizzell, 1999; Sheppard & Welsh, 1999).  
 
Drugs targeting PDEs are being considered for their cardiotonic, pulmonary 
vasodilator, smooth muscle relaxant, antithrombotic, antiinflammtory, and antiasthmatic 
properties (Conti & Beavo, 2007). Targeted inhibition of PDE4 has been pursued as a 
way of reducing inflammation in patients with asthma or COPD, diseases characterized 
by mucus-congested and inflamed airways (Barnette, 1999; Compton et al., 2001). 
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Cilomilast and roflumilast, two second generation PDE4 inhibitors, have shown potential 
benefit for treatment of asthma and COPD.  However, clinical utility of PDE4 inhibitors 
has been limited by adverse effects, including nausea, diarrhea, and vomiting (Fan 
Chung, 2006; Halpin, 2008).  
 
Although PDE3 inhibitors do not appear to have direct anti-inflammatory actions, 
they have been shown to augment the anti-inflammatory actions of PDE4 inhibitors 
(Giembycz et al., 1996; Schudt et al., 1995). Also, PDE3 inhibitors could act as 
bronchodilators and may have synergistic effects with PDE4 inhibitors (Halpin, 2008). 
Development of dual specificity inhibitors (such as dual PDE3-PDE4 inhibitors) may 
provide more bronchodilator and bronchoprotective effect in addition to the beneficial 
PDE4 effects (Giembycz, 2005).  
 
PDE3 and PDE4 have been reported to be the major PDEs present in airway 
epithelial cells (Torphy, 1998; Wright et al., 1998). Inhibition of PDE4 and/or PDE3 has 
been demonstrated to activate CFTR Cl- channel function (Cobb et al., 2003; Kelley et 
al., 1995; Liu et al., 2005). However, the mechanism through which the functional 
coupling occurs remains unclear. In this study, we demonstrated that PDE3A is 
physically and functionally coupled to CFTR and form macromolecular complexes 
together with other signaling molecules. Inhibition of PDE3A augments CFTR Cl- 
channel function by generation of highly compartmentalized cAMP. However, inhibition 
of PDE4 using rolipram led to globally increased cAMP. These findings not only provide 
insights into the important roles of PDE3A in compartmentalized cAMP signaling 
processes, but may also have important implications in the therapeutic interventions of 
diseases such as CF, asthma, and COPD: 1) targeting PDE3A and development of 
isoform-specific PDE3A inhibitors (or dual specificity inhibitors) may open new avenue 
in PDEs drug development, 2) inhibition of PDE3A has the beneficial effects of localized 
potentiation of CFTR channel function (through compartmentalized signaling) and thus 
submucosal gland secretion. These additional benefits would help to restore and maintain 
airway and lung health. 
 
In this study, we have identified that compartmentalized cAMP at the plasma 
membrane is generated by inhibiting PDE3A, which is functionally and physically 
coupled to the CFTR chloride channel and thus to tracheal mucosal secretion. We suggest 
that PDE3A and CFTR are in close proximity to each other on the plasma membrane. 
Inhibition of PDE3A lead to generation of compartmentalized cAMP at the plasma 
membrane, which, in turn, lead to increased clustering of these two proteins and the 
maintenance of a high degree of specificity. Actin cytoskeleton disruption altered PDE3A 
dynamics and its physical and functional coupling with CFTR. Such regulation of CFTR 
function via its interaction with PDE3A might be of physiological relevance owing to the 
relevance of CFTR in fluid transport and homeostasis.
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